These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 30905033)
21. All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism. Roetker NS; Lutsey PL; Zakai NA; Alonso A; Adam TJ; MacLehose RF Thromb Haemost; 2018 Sep; 118(9):1637-1645. PubMed ID: 30103250 [TBL] [Abstract][Full Text] [Related]
22. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Imberti D; Pomero F; Benedetti R; Fenoglio L Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399 [TBL] [Abstract][Full Text] [Related]
23. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Gao JH; Chu XC; Wang LL; Ning B; Zhao CX Medicine (Baltimore); 2017 Oct; 96(40):e8059. PubMed ID: 28984761 [TBL] [Abstract][Full Text] [Related]
24. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants. Vedovati MC; Giustozzi M; Becattini C Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513 [TBL] [Abstract][Full Text] [Related]
25. [Direct oral anticoagulants in the treatment of cancer-associated thrombosis]. Stebler-Fontaine L; Rossel A; Marti C; Righini M; Robert-Ebadi H Rev Med Suisse; 2019 Dec; 15(674):2232-2235. PubMed ID: 31804034 [TBL] [Abstract][Full Text] [Related]
26. The Role of New Oral Anticoagulants (NOACs) in Cancer Patients. Ravikumar R; Lim CS; Davies AH Adv Exp Med Biol; 2017; 906():137-148. PubMed ID: 27620312 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794 [TBL] [Abstract][Full Text] [Related]
28. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials. Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879 [TBL] [Abstract][Full Text] [Related]
29. Direct oral anticoagulants: An update. Franco Moreno AI; Martín Díaz RM; García Navarro MJ Med Clin (Barc); 2018 Sep; 151(5):198-206. PubMed ID: 29295790 [TBL] [Abstract][Full Text] [Related]
30. Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis. Feng W; Wang X; Huang D; Lu A Pharmacol Res; 2021 Apr; 166():105438. PubMed ID: 33540046 [TBL] [Abstract][Full Text] [Related]
31. Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long? Howard LS Expert Rev Respir Med; 2018 May; 12(5):387-402. PubMed ID: 29542359 [TBL] [Abstract][Full Text] [Related]
32. Target-specific Oral Anticoagulants in the Emergency Department. Peacock WF; Levy PD; Gonzalez MG; Than M J Emerg Med; 2016 Feb; 50(2):246-57. PubMed ID: 26614713 [TBL] [Abstract][Full Text] [Related]
33. New anticoagulants for the treatment of venous thromboembolism. Fernandes CJ; Alves Júnior JL; Gavilanes F; Prada LF; Morinaga LK; Souza R J Bras Pneumol; 2016 Apr; 42(2):146-54. PubMed ID: 27167437 [TBL] [Abstract][Full Text] [Related]
34. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study. Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043 [TBL] [Abstract][Full Text] [Related]
35. Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'. Kakkos SK; Kirkilesis GI; Tsolakis IA Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):127. PubMed ID: 25882231 [No Abstract] [Full Text] [Related]
36. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study. Badreldin H J Thromb Thrombolysis; 2018 Jul; 46(1):16-21. PubMed ID: 29626281 [TBL] [Abstract][Full Text] [Related]
37. Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting. Nielsen A; Poulsen PB; Dybro L; Kloster B; Lorentzen A; Olsen J; Kümler T J Med Econ; 2019 Dec; 22(12):1321-1327. PubMed ID: 31516054 [No Abstract] [Full Text] [Related]
38. Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials. Tomkowski W; Kuca P; Bignamini AA; Andreozzi GM Int Angiol; 2017 Oct; 36(5):496-497. PubMed ID: 28641408 [No Abstract] [Full Text] [Related]
39. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187 [TBL] [Abstract][Full Text] [Related]
40. [The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020]. Auditeau C; Talbot A; Blandinières A; Smadja DM; Gendron N Bull Cancer; 2020 May; 107(5):574-585. PubMed ID: 32252973 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]